Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 4
2015 1
2016 1
2017 3
2018 1
2021 2
2022 2
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean jia xing lin[Author] (1 results)?
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial.
Liu SM, Tu HY, Wei XW, Yan HH, Dong XR, Cui JW, Zhou Z, Xu CR, Zheng MY, Li YS, Wang Z, Bai XY, Li AN, Sun YL, Huang J, Lin JX, Ke EE, Xu BF, Lu C, Du Y, Chen Y, Ma R, Wang BH, Cang SD, Wang BC, Chen HJ, Yang JJ, Li Y, Zhou Q, Wu YL. Liu SM, et al. Among authors: lin jx. Nat Med. 2023 Aug;29(8):2079-2086. doi: 10.1038/s41591-023-02461-x. Epub 2023 Jul 24. Nat Med. 2023. PMID: 37488286 Clinical Trial.
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.
Dong ZY, Zhong WZ, Zhang XC, Su J, Xie Z, Liu SY, Tu HY, Chen HJ, Sun YL, Zhou Q, Yang JJ, Yang XN, Lin JX, Yan HH, Zhai HR, Yan LX, Liao RQ, Wu SP, Wu YL. Dong ZY, et al. Among authors: lin jx. Clin Cancer Res. 2017 Jun 15;23(12):3012-3024. doi: 10.1158/1078-0432.CCR-16-2554. Epub 2016 Dec 30. Clin Cancer Res. 2017. PMID: 28039262
Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapy.
Tu HY, Yin K, Zhao X, Ke EE, Wu SP, Li YS, Zheng MM, Liu SM, Xu CR, Sun YL, Lin JX, Bai XY, Zhang YC, Zhou Q, Yang JJ, Zhong WZ, Wang BC, Zhang XC, Zhu D, Yang L, Ou Q, Wu YL. Tu HY, et al. Among authors: lin jx. Mol Oncol. 2023 Aug;17(8):1581-1594. doi: 10.1002/1878-0261.13439. Epub 2023 Apr 29. Mol Oncol. 2023. PMID: 37078460 Free PMC article.
PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial.
Maggie Liu SY, Huang J, Deng JY, Xu CR, Yan HH, Yang MY, Li YS, Ke EE, Zheng MY, Wang Z, Lin JX, Gan B, Zhang XC, Chen HJ, Wang BC, Tu HY, Yang JJ, Zhong WZ, Li Y, Zhou Q, Wu YL. Maggie Liu SY, et al. Among authors: lin jx. Sci Bull (Beijing). 2024 Feb 26;69(4):535-543. doi: 10.1016/j.scib.2023.12.046. Epub 2023 Dec 26. Sci Bull (Beijing). 2024. PMID: 38185589 Free article. Clinical Trial.
Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.
Tu HY, Li YS, Bai XY, Sun YL, Zheng MY, Ke EE, Liao RQ, Jiang BY, Lin JX, Huang J, Xu BF, Yang JJ, Zhang XC, Zhou Q, Wang BC, Chen HJ, Tong X, Yu R, Wu X, Zhu D, Wu YL. Tu HY, et al. Among authors: lin jx. Clin Lung Cancer. 2022 Mar;23(2):135-142. doi: 10.1016/j.cllc.2021.09.002. Epub 2021 Sep 20. Clin Lung Cancer. 2022. PMID: 34645582
CD146 as an adverse prognostic factor in uterine sarcoma.
Zhou Y, Huang H, Yuan LJ, Xiong Y, Huang X, Lin JX, Zheng M. Zhou Y, et al. Among authors: lin jx. Eur J Med Res. 2015 Aug 21;20(1):67. doi: 10.1186/s40001-015-0160-2. Eur J Med Res. 2015. PMID: 26293576 Free PMC article.
18 results